PCM
AVDL

Palisade Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Palisade Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-27,000
Closed -$119K – 448
2018
Q3 		$119K Buy
27,000
+12,000
+80% +$64.8K ﹤0.01% 455
2018
Q2 		$92K Buy
15,000
+4,000
+36% +$28.1K ﹤0.01% 453
2018
Q1 		$80K Buy
+11,000
New +$96.8K ﹤0.01% 440

Other funds holding AVDL

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Palisade Capital Management's AVDL Position: Q4 2018 in Review

Palisade Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q4 2018, closing a stake of 27,000 shares — an estimated $119K sold.

Palisade Capital Management first reported a position in AVDL in Q1 2018 and held it in 3 quarters. The position peaked at $119K in Q3 2018. 59 funds tracked by Wall St. Rank hold AVDL as of Q4 2018.

  • Palisade Capital Management reported no remaining Avadel Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Palisade Capital Management sold 27,000 Avadel Pharmaceuticals shares in Q4 2018, an estimated $119K.
  • Palisade Capital Management first reported a position in Avadel Pharmaceuticals in Q1 2018 and held it in 3 quarters.
  • Palisade Capital Management's Avadel Pharmaceuticals position peaked at $119K in Q3 2018.
  • 59 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2018.

Based on Palisade Capital Management's 13F filing for Q4 2018, filed 12 Feb 2019.